menu
    • menu

    Company profile for Mitsubishi Tanabe Pharma

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in two business segments. The Medical Supplies segment is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Others segment is engaged in the manufacture, purchase and sale of chemical products, as well as the ...
    Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in two business segments. The Medical Supplies segment is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Others segment is engaged in the manufacture, purchase and sale of chemical products, as well as the management of real estate. As of March 31, 2014, the Company had 33 subsidiaries and five associated companies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mitsubishi Tanabe Pharmajapan Flag
    Country
    Country
    Japan
    Address
    Address
    Yodoyabashi Square 2-6-18, Kitahama, Chuo-kuOSAKA-SHI, OSK 541-8505
    Telephone
    Telephone
    +81-6-62055085
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mt-pharma.co.jp/e/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/mitsubishi-tanabe-pharma-corporation
    youtube
    YouTube
    Twitter
    Twitter
    https://twitter.com/mtpa_us?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI India 2024

    CPhI India 2024

    Not Confirmed

    envelop Contact Supplier

    CPhI India 2024

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “LGM Pharma has made significant strides in meeting the evolving needs of its clients”

    “LGM Pharma has made significant strides in meeting the evolving needs of its clients”

    This week, SpeakPharma interviews four senior executives of LGM Pharma — Shailesh Vengurlekar (Senior VP, Quality and Regulatory Affairs), Deepak Thassu (Senior VP, R&D and Regulatory Submission), Selwyn Lustman (Senior VP, Global Sourcing and Procurement), and Mike Stenberg (VP, Business Development). The four VPs talk about expansion in manufacturing capabilities of the Florida-based contract development and manufacturing organization (CDMO), expertise that makes LGM a strong partner and the criteria it adopts while selecting its suppliers.  HIGHLIGHTS// expansion in manufacturing capabilities/ expertise that makes LGM a strong partner/ criteria for selecting its suppliers LGM Pharma recently invested heavily in expanding its CDMO capabilities by 50 percent. Can you share why offering standalone analytical testing services is important to LGM Pharma’s growth strategy? How does it benefit your clients? Vengurlekar: This recent expansion in CDMO capabilities is part of LGM Pharma’s growth strategy that lays importance on diversification. One key area of this diversification is the offering of standalone Analytical Testing Services (ATS). This service plays a crucial role in supporting our clients by providing them with greater flexibility and reliability. LGM Pharma is already a well-established leader in the API supply chain. We have now identified a significant need in the market and are now serving compounding pharmacies, including 503A and 503B facilities. These pharmacies not only require high-quality, GMP-compliant APIs, but also need a trusted, compliant, and capable laboratory to analyze both their APIs and compounded products. Recognizing this opportunity to further support our clients, LGM Pharma has expanded into ATS. We have witnessed tremendous growth since we’ve launched these services. By offering ATS under a separate legal entity — LGM Pharma Solutions — we are able to provide an additional layer of flexibility to our clients. This structure eliminates any conflict of interest. While LGM Pharma LLC handles API supply, LGM Pharma Solutions focuses on delivering top-tier ATS, all under the same LGM Pharma umbrella. This setup enhances trust and allows our clients to work with us more seamlessly. HIGHLIGHTS// diversified into standalone ATS/ well-established leader in API supply chain/ serving compounding pharmacies/ offering APIs and ATS under different legal entities. While suppositories offer clear advantages for certain medications, can you describe how LGM Pharma plans to leverage its expertise in this area to address specific unmet needs in the growing women’s health market? Thassu: We’re taking a dual approach to enhance both our R&D and manufacturing capabilities. First, we’ve introduced a new semi-automatic machine that allows us to produce smaller batches more efficiently. This is particularly important for the suppository segment, where demand doesn’t require large-scale production. The new system enables quicker adjustments to the manufacturing process, providing us with greater flexibility of producing small batches. Second, many of the materials we handle in the women’s health sector are sensitive to heat, light, and oxygen. To address this, we’re upgrading our facility to accommodate these specialized requirements. This ensures we can develop and manufacture products while maintaining the integrity of heat-, light-, and oxygen-sensitive ingredients. Additionally, we’re working closely with clients to prepare for various technical challenges. Whether it’s processing homeopathic ingredients or handling delicate fermentation-based materials, which are highly sensitive to both light and heat, our team has upgraded its skills and equipment to manage these complexities. From technology advancements in manufacturing to specialized handling conditions and improved technical expertise, we’ve made significant strides to ensure we can meet the evolving needs of our clients and their products. HIGHLIGHTS// dual approach to enhance R&D and manufacturing capabilities/ upgrading facilities to accommodate specialized requirements/ working with clients to address challenges. The pandemic underscored supply chain problems. Can you detail the specific criteria LGM Pharma uses while selecting suppliers for its manufacturing processes? Lustman: LGM looks at many facets of a manufacturer before proceeding to approve them for a specific project. We start by checking their regulatory history with the US Food and Drug Administration (FDA) and other authorities. We try to find out if they have received any warning letters. What is their inspection history? Have they received NAIs (no action indicated) and VAIs (voluntary action indicated)? We further investigate the company’s overall business status — we need to know that they are a stable partner to work with in the long term. Manufacturers are then assessed for their overall technology and the number of employees working in various fields, such as R&D, quality control, quality assurance, regulatory affairs, manufacturing, and the educational levels of these employees. Once we have established that the manufacturer is a potential partner, we check their status for a particular project. We look at their advantages, and whether they have a non-infringing route of synthesis (ROS) that will allow early launch. Are they developing a second process that will be more competitive in pricing? And, does the manufacturer have the necessary capacity and/or spare capacity for the project that we are assessing? We need to know whether the drug master file (DMF) has been registered, the current batch size, and the potential for increase in batch size. Pricing is a key indicator — we need to know whether the pricing of the manufacturer is competitive or not, and if the manufacturer will be able to compete in the future as the project matures. LGM always assesses for quality, price, and delivery. Goods must be of the correct quality, at the right price, with delivery time as desired, in order to meet commercial needs. HIGHLIGHTS// investigate various facets of manufacturer before approving them for a project/ look at advantages, non-infringing ROS/ assess for quality, price, delivery Can you highlight specific capabilities and experiences LGM Pharma possesses that make it a strong partner for companies developing antibody-drug-conjugates (ADCs)? Stenberg: ADCs are often peptides linked with small molecules. However, they may also be peptides linked with oligonucleotides. Regardless, LGM can help manage the supply chain associated with the components that are used in the conjugation of the ADC. LGM has extensive experience, and an extensive network around sourcing and managing the supply chain associated with ADC components. LGM’s experience and capabilities extend to sourcing peptides, small molecules or oligonucleotides used in the conjugation process. Additionally, given our deep relationships in the supply chain aspect of this process, LGM may also be able to identify partners who can help with the conjugation process itself. HIGHLIGHTS// extensive experience, network around sourcing, managing supply chain associated with ADC components / identify partners that can help with conjugation process

    Impressions: 466

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients

    #SpeakPharma With LGM Pharma
    09 Nov 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments

    Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments

    This year has seen pivotal advancements in medical innovation. The US Food and Drug Administration (FDA) has approved several groundbreaking therapies that promise to transform patient care across multiple therapeutic areas.Some of the therapies approved have revolutionary delivery mechanisms, while others are first-in-class treatments for previously unaddressed conditions. This week, PharmaCompass brings you a compilation of new pathbreaking approvals of 2024, including advancements in neurology, chronic conditions, mental health conditions, and innovative solutions for various other ailments.Lilly, Alpha Cognition, BMS transform neurological care with new Alzheimer’s, schizophrenia drugsThe neurological treatment landscape saw several major breakthroughs in 2024, particularly in the treatment of Alzheimer’s disease (AD). Eli Lilly’s Kisunla represents a significant advancement in treating early, symptomatic AD. Following decades of failed efforts, Kisunla’s approval, along with that of Eisai-Biogen’s Leqembi last year, marks a turning point in addressing AD.The drug works by targeting and clearing beta amyloid plaque from the brain, thereby attacking the disease’s underlying pathology, rather than just managing symptoms. Administered as an infusion every four weeks, Kisunla’s Medicare coverage makes it accessible to patients in the US who desperately need new treatment options. Alpha Cognition’s Zunveyl emerged as a promising new oral treatment for mild-to-moderate Alzheimer’s-related dementia. Only the second oral AD treatment approved by the FDA in over a decade, Zunveyl is a prodrug, or a biologically inactive compound that can be metabolized by the body to produce a drug. It remains inactive as it passes through the stomach and enhances cholinergic function in the brain.Perhaps one of the most exciting breakthroughs of 2024 was Bristol-Myers Squibb’s Cobenfy. This revolutionary antipsychotic medication for schizophrenia represents the first novel approach to treatment since the 1950s. Unlike traditional antipsychotics that target dopamine receptors, Cobenfy works through cholinergic receptors, offering new hope to patients who struggle with the side effects of conventional treatments.Traditional antipsychotics have been associated with several mild and serious side effects such as weight gain, feeling unmotivated and sluggish, high rates of cardiac disease, and even early death. Cobenfy’s innovative mechanism of action has generated excitement in the medical community. Experts project Cobenfy to bring in US$ 7.5 billion in peak annual sales, thereby validating BMS’ recent, US$ 14-billion acquisition of Karuna Therapeutics.Verona, Sanofi’s drugs revolutionize COPD care; Madrigal’s Rezdiffra offers hope to MASH patients The landscape of chronic obstructive pulmonary disease (COPD) treatment saw remarkable advances in 2024. Verona Pharma’s Ohtuvayre brings the first new mechanism of action in over two decades for COPD treatment. This dual-action, inhaled medication serves as both a bronchodilator and an anti-inflammatory agent, offering a comprehensive approach to symptom management.Adding to this progress, Sanofi and Regeneron’s Dupixent achieved a historic milestone by becoming the first biologic approved for treating COPD. Dupixent is Sanofi’s best-selling drug. It is poised to cross over € 21 billion (US$ 23.5 billion) in sales by 2030, with COPD likely to contribute US$ 2.9 billion, predict analysts. Over 390 million people are living with COPD worldwide.In the field of liver disease, Madrigal Pharmaceuticals’ Rezdiffra became the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring. This approval represents a breakthrough in a field that has been notorious for being a graveyard for failed programs. Rezdiffra offers hope to patients with this common liver condition, which primarily affects those with obesity or type 2 diabetes. The American Liver Foundation has termed this approval a “game-changing” moment in hepatology.For the rare disease community, Ipsen’s Iqirvo emerged as the first new medicine approved in nearly a decade for primary biliary cholangitis (PBC). This first-in-class peroxisome proliferator-activated receptor (PPAR) agonist offers new hope for the approximately 100,000 Americans affected by this condition, particularly women aged 30 to 60 years.A significant breakthrough for patients with hypoparathyroidism came with the approval of Ascendis’ Yorvipath, making it the only treatment for hypoparathyroidism in adults. By directly addressing the underlying hormone deficiency, Yorvipath helps stabilize calcium levels in the blood, reducing the treatment burden associated with managing symptoms through calcium and vitamin D supplements alone.In the realm of pulmonary medicine, Merck’s Winrevair emerged as the first new therapy for pulmonary arterial hypertension (PAH) in over a decade. As the first approved activin-signaling inhibitor therapy, Winrevair represents a novel approach to treating this rare but severe condition that doctors call a “ticking time bomb”. The drug is the first treatment that targets the underlying cause of the lung condition, which typically leads to death within a decade of diagnosis.ARS Pharma launches nasal spray alternative to EpiPen, Eicos introduces med for severe frostbiteLeading the charge in innovative drug delivery is ARS Pharma’s Neffy, the first-ever nasal spray alternative to the EpiPen for treating severe allergic reactions. This groundbreaking advancement represents the first major innovation in anaphylaxis treatment in over a decade. For children and individuals with needle phobia, this nasal spray format addresses one of the most significant barriers to timely treatment of allergic emergencies. Speaking of emergency medicine, Eicos Sciences’ Aurlumyn made history as the first FDA-approved treatment for severe frostbite. This approval fills a critical gap in emergency care, offering a medical intervention that could prevent the need for amputation in severe cases.The cardiovascular space saw its first oral anti-hypertensive therapy that works through a new therapeutic pathway in almost 40 years. Idorsia’s Tryvio is a treatment for hypertension that offers new hope to patients whose blood pressure remains inadequately controlled on existing medications. Idorsia expects millions of patients to benefit from it.Our view This year, the pharmaceutical industry has taken a remarkable leap forward by addressing some of healthcare’s most challenging conditions. Treatments like BMS’ Cobenfy for schizophrenia and Madrigal’s Rezdiffra for MASH demonstrate the industry’s growing ability to translate science into practical therapies. With the growing use of artificial intelligence in the drug industry, we hope that these approvals are just a precursor to a bevy of pathbreaking therapies in the years to come. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 610

    https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments

    #Phispers by PHARMACOMPASS
    14 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Mitsubishi Tanabe Presents Radicava® Ph 3 Results At NEALS 2024
    Mitsubishi Tanabe Presents Radicava® Ph 3 Results At NEALS 2024

    21 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-presents-new-results-of-radicava-ors-edaravone-from-a-phase-3b-efficacy-and-safety-extension-study-and-a-clinical-analysis-of-multiple-studies-at-neals-2024-302280605.html

    PR NEWSWIRE
    21 Oct 2024
    Share Share
    Mitsubishi Tanabe Pharma Unveils New ALS Findings At NEALS 2024
    Mitsubishi Tanabe Pharma Unveils New ALS Findings At NEALS 2024

    17 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-unveils-new-als-research-findings-at-neals-2024-annual-meeting-302278438.html

    PR NEWSWIRE
    17 Oct 2024
    Share Share
    Mitsubishi America to Showcase ALS Research at 2024 AANEM Meeting
    Mitsubishi America to Showcase ALS Research at 2024 AANEM Meeting

    15 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-showcase-als-research-at-2024-aanem-annual-meeting-302275445.html

    PR NEWSWIRE
    15 Oct 2024
    Share Share
    Mitsubishi Tanabe Presents RADICAVA ORS Data At AMCP Nexus
    Mitsubishi Tanabe Presents RADICAVA ORS Data At AMCP Nexus

    10 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-showcase-new-radicava-ors-edaravone-real-world-data-at-2024-academy-of-managed-care-pharmacy-nexus-meeting-302272093.html

    PR NEWSWIRE
    10 Oct 2024
    Share Share
    Mitsubishi Tanabe To Present Radicava ORS® Data At NASP Meeting
    Mitsubishi Tanabe To Present Radicava ORS® Data At NASP Meeting

    06 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-radicava-ors-edaravone-data-at-the-2024-national-association-of-specialty-pharmacy-annual-meeting-302267885.html

    PR NEWSWIRE
    06 Oct 2024
    Share Share
    Mitsubishi Tanabe Presents Ph 3 Data of ND0612 In Parkinson
    Mitsubishi Tanabe Presents Ph 3 Data of ND0612 In Parkinson

    30 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-presents-open-label-extension-outcomes-and-additional-data-from-phase-3-boundless-trial-of-investigational-nd0612-in-parkinsons-disease-302261504.html

    PR NEWSWIRE
    30 Sep 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Argatroban Monohydrate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Argatroban Monohydrate

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS JDMF arrow-down
    ✖

    Registration Number : 228MF10013

    Registrant's Address : Osaka Prefecture, Osaka City, Chuo Ward, Doshomachi 3-2-10

    Initial Date of Registration : 2016-01-08

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Argatroban Monohydrate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Argatroban Monohydrate

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS JDMF arrow-down
    ✖

    Registration Number : 222MF10221

    Registrant's Address : 3-16-89 Kashima, Yodogawa-ku, Osaka City, Osaka Prefecture

    Initial Date of Registration : 2010-08-23

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Diltiazem Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Diltiazem Hydrochloride

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 3059

    Submission : 1977-11-11

    Status : Inactive

    Type : II

     CEP/COS Inactive-api
    ✖

    Certificate Number : R1-CEP 2001-177 - Rev 05

    Issue Date : 2015-10-19

    Type : Chemical

    Substance Number : 1004

    Status : Withdrawn by Holder

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : HKINNOEN Co., Ltd.

    Registration Date : 2022-10-20

    Registration Number : 20221020-209-J-1386

    Manufacturer Name : Mitsubishi Tanabe Pharma Factory Ltd.

    Manufacturer Address : 7473-2, Ooaza Onoda, Sanyoonoda, Yamaguchi 756-0054, Japan

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Evocalcet

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Evocalcet

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS JDMF arrow-down
    ✖

    Registration Number : 229MF10027

    Registrant's Address : Osaka Prefecture, Osaka City, Chuo Ward, Doshomachi 3-2-10

    Initial Date of Registration : 2017-02-08

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Polyvinyl Alcohol API

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Polyvinyl Alcohol API

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2013-209 - Rev 00

    Issue Date : 2021-09-28

    Type : Chemical

    Substance Number : 1961

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Ursodeoxycholic Acid

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Ursodeoxycholic Acid

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 3312

    Submission : 1978-08-09

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Poly(vinyl alcohol), Viscosity 42.5...

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Poly(vinyl alcohol), Viscosity 42.5...

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2022-281 - Rev 02

    Issue Date : 2024-06-26

    Type : Chemical

    Substance Number : 1961

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    L-Threonine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    L-Threonine

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10061

    Submission : 1993-01-26

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Lysine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Lysine

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10062

    Submission : 1993-01-26

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Proline

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Proline

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10063

    Submission : 1993-01-26

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    2-n-butyl-1h-imidazole-4-carboxaldeh...

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    02

    Amino Acid Mixture

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    03

    Amino Acid Mixture Abbc

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    04

    Amino Acid Mixture Abbu

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    05

    Amino Acid Mixture Abbx

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    06

    Benzyl S-1,2,3,4-tetrahydroisoquinol...

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    07

    Diltiazem Hcl

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    08

    Diltiazem Hydrochloride (process C)

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    09

    Diltiazem Malate

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow

    10

    Dl - Methionine

    Japan
    euroPLX 86 Munich
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    JDMF

    read-more
    read-more

    01

    Argatroban hydrate

    JDMF

    American Pharma Summit
    Not Confirmed
    arrow

    Argatroban hydrate

    Japan
    arrow
    American Pharma Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Japan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Mitsubishi Tanabe Pharma

    Registration Number : 222MF10221

    Registrant's Address : 3-16-89 Kashima, Yodogawa-ku, Osaka City, Osaka Prefecture

    Initial Date of Registration : 2010-08-23

    Latest Date of Registration : 2017-02-08

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Argatroban hydrate

    JDMF

    American Pharma Summit
    Not Confirmed
    arrow

    Argatroban hydrate

    Japan
    arrow
    American Pharma Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Japan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Mitsubishi Tanabe Pharma

    Registration Number : 228MF10013

    Registrant's Address : Osaka Prefecture, Osaka City, Chuo Ward, Doshomachi 3-2-10

    Initial Date of Registration : 2016-01-08

    Latest Date of Registration : 2016-01-08

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Ebokaruseto

    JDMF

    American Pharma Summit
    Not Confirmed
    arrow

    Ebokaruseto

    Japan
    arrow
    American Pharma Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Japan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Mitsubishi Tanabe Pharma

    Registration Number : 229MF10027

    Registrant's Address : Osaka Prefecture, Osaka City, Chuo Ward, Doshomachi 3-2-10

    Initial Date of Registration : 2017-02-08

    Latest Date of Registration : 2017-12-25

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mitsubishi Tanabe Presents Data from Phase 3 BouNDless Trial of ND0612 in Parkinson's

    Details:

    ND0612 is a continuous, subcutaneous infusion levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.


    Lead Product(s): Etilevodopa,Carbidopa

    Therapeutic Area: Neurology Brand Name: ND0612

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 30, 2024

    blank

    01

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Etilevodopa,Carbidopa

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Mitsubishi Tanabe Presents Data from Phase 3 BouNDless Trial of ND0612 in Parkinson's

    Details : ND0612 is a continuous, subcutaneous infusion levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.

    Brand Name : ND0612

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Moderna and Mitsubishi Tanabe Sign Agreement for mRNA Vaccines in Japan

    Details:

    Moderna and Mitsubishi entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.


    Lead Product(s): Covid-19 Vaccine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Spikevax

    Study Phase: ApprovedProduct Type: Vaccine

    Recipient: Moderna Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement July 08, 2024

    blank

    02

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Covid-19 Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Recipient : Moderna Therapeutics

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Moderna and Mitsubishi Tanabe Sign Agreement for mRNA Vaccines in Japan

    Details : Moderna and Mitsubishi entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.

    Brand Name : Spikevax

    Molecule Type : Vaccine

    Upfront Cash : Undisclosed

    July 08, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acquisition of Argatroban Business in Europe

    Details:

    Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.


    Lead Product(s): Argatroban Monohydrate

    Therapeutic Area: Hematology Brand Name: Arganova

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Ethypharm

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition June 17, 2024

    blank

    03

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Argatroban Monohydrate

    Therapeutic Area : Hematology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Ethypharm

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Acquisition of Argatroban Business in Europe

    Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.

    Brand Name : Arganova

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    June 17, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    USD 10.8 Mn Invested in New Drug Development for Malaria with Japanese Pharma Partners

    Details:

    The net proceeds will be used for the lead optimization of a novel and very promising T. cruzi active series being developed for the treatment of Chagas disease.


    Lead Product(s): Undisclosed

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: DiscoveryProduct Type: Undisclosed

    Sponsor: The Global Health Innovative Technology

    Deal Size: $1.9 million Upfront Cash: Undisclosed

    Deal Type: Funding May 08, 2024

    blank

    04

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Discovery

    Partner/Sponsor/Collaborator : The Global Health Innovative Technology

    Deal Size : $1.9 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    USD 10.8 Mn Invested in New Drug Development for Malaria with Japanese Pharma Partners

    Details : The net proceeds will be used for the lead optimization of a novel and very promising T. cruzi active series being developed for the treatment of Chagas disease.

    Brand Name : Undisclosed

    Molecule Type : Undisclosed

    Upfront Cash : Undisclosed

    May 08, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mitsubishi Tanabe Pharma America Receives Orphan Drug Exclusivity for RADICAVA ORS®

    Details:

    Radicava ORS (edaravone) is a free radical scavenger available in the form of oral suspension, which is approved by USFDA for the treatment of amyotrophic lateral sclerosis.


    Lead Product(s): Edaravone

    Therapeutic Area: Neurology Brand Name: Radicava ORS

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 08, 2024

    blank

    05

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Edaravone

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Mitsubishi Tanabe Pharma America Receives Orphan Drug Exclusivity for RADICAVA ORS®

    Details : Radicava ORS (edaravone) is a free radical scavenger available in the form of oral suspension, which is approved by USFDA for the treatment of amyotrophic lateral sclerosis.

    Brand Name : Radicava ORS

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 08, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Expiration of Marketing Alliance for TENELIA® and CANAGLU® Tablets

    Details:

    Daiichi will transfer distribution rights for Tenelia (teneligliptin) to Mitsubishi, ending joint medical information activities for all products.


    Lead Product(s): Teneligliptin Hydrobromide

    Therapeutic Area: Endocrinology Brand Name: Tenelia

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Daiichi Sankyo

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Termination March 04, 2024

    blank

    06

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Teneligliptin Hydrobromide

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Daiichi Sankyo

    Deal Size : Undisclosed

    Deal Type : Termination

    DEALS_DEV arrow-down

    Expiration of Marketing Alliance for TENELIA® and CANAGLU® Tablets

    Details : Daiichi will transfer distribution rights for Tenelia (teneligliptin) to Mitsubishi, ending joint medical information activities for all products.

    Brand Name : Tenelia

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    March 04, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson's Disease at 2023 International Congress of Parkinson's Disease and Movement Disor...

    Details:

    ND0612 is an investigative drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for people with Parkinson’s disease (PD) experiencing motor fluctuations.


    Lead Product(s): Etilevodopa,Carbidopa

    Therapeutic Area: Neurology Brand Name: ND0612

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: NeuroDerm

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 28, 2023

    blank

    07

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Etilevodopa,Carbidopa

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : NeuroDerm

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson's Disease at 2023 Internatio...

    Details : ND0612 is an investigative drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for people with Parkinson’s disease (PD) experiencing motor fluctuations.

    Brand Name : ND0612

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    August 28, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    New Launch Of Mounjaro 2.5mg/5mg Ateos The World's First Sustained Release GIP/GLP-1 Receptor Agonist

    Details:

    Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist, which enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner.


    Lead Product(s): Tirzepatide

    Therapeutic Area: Endocrinology Brand Name: Mounjaro

    Study Phase: ApprovedProduct Type: Peptide

    Recipient: Eli Lilly

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 18, 2023

    blank

    08

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tirzepatide

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved

    Recipient : Eli Lilly

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    New Launch Of Mounjaro 2.5mg/5mg Ateos The World's First Sustained Release GIP/GLP-1 Receptor Agon...

    Details : Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist, which enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner.

    Brand Name : Mounjaro

    Molecule Type : Peptide

    Upfront Cash : Not Applicable

    April 18, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mitsubishi Tanabe Pharma America Announces Enrollment Completion for Global, Phase 3b Study of RADICAVA ORS® (edaravone) in ALS

    Details:

    Radicava ORS (edaravone) is a free radical scavenger used to delay the progression of amyotrophic lateral sclerosis (ALS) due to the therapeutic effect of its known antioxidant properties as oxidative stress kills neurons in patients with ALS.


    Lead Product(s): Edaravone

    Therapeutic Area: Neurology Brand Name: Radicava ORS

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 23, 2023

    blank

    09

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Edaravone

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Mitsubishi Tanabe Pharma America Announces Enrollment Completion for Global, Phase 3b Study of RAD...

    Details : Radicava ORS (edaravone) is a free radical scavenger used to delay the progression of amyotrophic lateral sclerosis (ALS) due to the therapeutic effect of its known antioxidant properties as oxidative stress kills neurons in patients with ALS.

    Brand Name : Radicava ORS

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    March 23, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mitsubishi Tanabe Pharma America Announces 48-Week Results from Global, Open-Label, Phase 3 Trial of RADICAVA ORS® (edaravone) in ALS

    Details:

    Radicava ORS (edaravone) is a free radical scavenger used to delay the progression of amyotrophic lateral sclerosis (ALS) due to the therapeutic effect of its known antioxidant properties as oxidative stress kills neurons in patients with ALS.


    Lead Product(s): Edaravone

    Therapeutic Area: Neurology Brand Name: Radicava ORS

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 27, 2023

    blank

    10

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed

    Mitsubishi Tanabe Pharma

    Japan
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Edaravone

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Mitsubishi Tanabe Pharma America Announces 48-Week Results from Global, Open-Label, Phase 3 Trial ...

    Details : Radicava ORS (edaravone) is a free radical scavenger used to delay the progression of amyotrophic lateral sclerosis (ALS) due to the therapeutic effect of its known antioxidant properties as oxidative stress kills neurons in patients with ALS.

    Brand Name : Radicava ORS

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    February 27, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Listed Products

    read-more
    read-more

    01

    Brand Name : Quali - V - I

    Spain

    arrow
    PPS Boston
    Not Confirmed

    02

    Brand Name : Quali-G

    Spain

    arrow
    PPS Boston
    Not Confirmed
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients by Ingredients

    Upload your portfolio for free, ask us

    Excipients By applications

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Mitsubishi Tanabe Pharma and get a quotation

    Mitsubishi Tanabe Pharma is a supplier offers 57 products (APIs, Excipients or Intermediates).

    Find a price of Argatroban Monohydrate bulk with JDMF offered by Mitsubishi Tanabe Pharma

    Find a price of Diltiazem Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Evocalcet bulk with JDMF offered by Mitsubishi Tanabe Pharma

    Find a price of Ursodeoxycholic Acid bulk with DMF offered by Mitsubishi Tanabe Pharma

    Find a price of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Amino Acids Mixture bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Argatroban bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Aspartic Acid API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Cholebine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Coleneuramide bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Diltiazem Malate bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Carnitine Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Histidine Monohydrochloride Monohydrate bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Phenylalanine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Threonine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Tryptophan bulk offered by Mitsubishi Tanabe Pharma

    Find a price of DL-Valine API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Glycine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Isoleucine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Alanine API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Arginine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Arginine Hydrochloride API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Asparagine Monohydrate bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Cysteine Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Glutamic Acid bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Glutamine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Histidine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Leucine API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Threonine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Tyrosine API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Tyrosine Ethyl Ester Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-VALINE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Lysine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Lysine Acetate bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Lysine Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Methionine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Netoglitazone bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Osemozotan Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Phenylalanine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Proline bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Serine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Ta 3090 bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Thiopental Sodium bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Thyrotropin-Releasing Hormone bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Tryptophan bulk offered by Mitsubishi Tanabe Pharma

    Find a price of FACILS., PERSONNEL & GENERAL OPERATING PROCEDS-OF TOKYO,JAPAN PLANT bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Y-39983 DRUG SUBSTANCE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of HER.TIAZEPN bulk offered by Mitsubishi Tanabe Pharma

    Find a price of FACILS.,PERSONNEL, & GENERAL OPERATING PROCEDS-ONODA, JAPAN PLANT bulk offered by Mitsubishi Tanabe Pharma

    Find a price of MT-7716 DRUG SUBSTANCE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of MP-513 DRUG SUBSTANCE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of FACILS.,PERSONNEL, & GENERAL OPERATING PROCEDS-OF OSAKA, JAPAN PLANT bulk offered by Mitsubishi Tanabe Pharma

    Find a price of MP-124 DRUG SUBSTANCE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of MCC-135 (BULK DRUG SUBSTANCE) bulk offered by Mitsubishi Tanabe Pharma

    Find a price of TA-5707F bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Aspirin bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Aspirin Lysinate bulk offered by Mitsubishi Tanabe Pharma

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search